The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase 0 exploratory study to assess the pharmacodynamic effects of single intratumoral dose of a novel bispecific targeting/immune-activating agent on the melanoma tumor microenvironment.
L. A. Fecher
Research Funding - Immunocore
Y. McGrath
Employment or Leadership Position - Immunocore
D. D. Williams
Employment or Leadership Position - Immunocore
N. J. Hassan
Employment or Leadership Position - Immunocore
M. Kalos
Research Funding - Immunocore
L. M. Schuchter
No relevant relationships to disclose
R. K. Amaravadi
No relevant relationships to disclose
A. Chew
Research Funding - Immunocore
E. A. Veloso
Research Funding - Immunocore
B. J. Czerniecki
No relevant relationships to disclose
G. Karakousis
No relevant relationships to disclose
G. P. Linette
Research Funding - Immunocore
B. K. Jakobsen
Employment or Leadership Position - Immunocore
Stock Ownership - Immunocore (B)
C. H. June
Research Funding - Immunocore